Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-13

  Zhang, Fan ^a   Zhang, Jie ^a   Liu, Moyan ^b   Zhao, Lichao ^b   Linghu, Ruixia ^a   Feng, Fan ^c   Gao, Xudong ^d   Jiao, Shunchang ^a   Zhao, Lei ^a,e   Hu, Yi ^a   Yang, Junlan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

^c GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^d BEIJING 302 HOSPITAL   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Calreticulin exposure; CrossMab; HER2 overexpressing breast cancer; Pertuzumab; T cell immunity; Trastuzumab

Indexed keywords

BISPECIFIC ANTIBODY; CALRETICULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PERTUZUMAB; PROTEIN KINASE B; TRAS PERMUT CROSSMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CELL DEATH; CELL PROLIFERATION; CELLULAR IMMUNITY; COMPETITIVE BINDING ASSAY; COMPLEMENTARITY DETERMINING REGION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAVY CHAIN; HUMAN; HUMAN CELL; LIGHT CHAIN; MOLECULAR DOCKING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

EID: 84954509305     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.994391     Document Type: Article

References (57)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12; PMID:2470152; http://dx.doi.org/10.1126/science.2470152
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82; PMID:3798106; http://dx.doi.org/10.1126/science.3798106
3. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15:2894-904; PMID:9256133
4. Emde A, K€ostler WJ, Yarden Y, on behalf of AROME. Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol 2012; 84:e49-57; PMID:20951604; http://dx.doi.org/10.1016/j.critrevonc.2010.09.002
5. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9:16-32; http://dx.doi.org/10.1038/nrclinonc.2011.177
6. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
7. Marty M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as firstline treatment: the M77001 study group. J Clin Oncol 2005; 23:4265-74; PMID:15911866; http://dx.doi.org/10.1200/JCO.2005.04.173
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/NEJM200103153441101
9. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8:215; PMID:17096862; http://dx.doi.org/10.1186/bcr1612
10. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2003; 5:317-28; http://dx.doi.org/10.1016/S1535-6108(04)00083-2
11. Cho H-S, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756-60; PMID:12610629; http://dx.doi.org/10.1038/nature01392
12. Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A et al. Pertuzumab monotherapy after trastuzumab based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30:1594-600; PMID:22393084; http://dx.doi.org/10.1200/JCO.2011.37.4207
13. Baselga J, Cortes J, Kim S-B, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216
14. Li B, Meng Y, Zheng L, Zhang X, Tong Q, Tan W, Hu S, Li H, Chen Y, Song J et al. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. Cancer Res 2013; 73:6471-83; PMID:24046294; http://dx.doi.org/10.1158/0008-5472.CAN-13-0657
15. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330-6; PMID:19934333; http://dx.doi.org/10.1158/0008-5472.CAN-08-4597
16. Nahta R, Hung M-C, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64:2343-6; PMID:15059883; http://dx.doi.org/10.1158/0008-5472.CAN-03-3856
17. Friess T. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005; 11:5300-9; PMID:16033849; http://dx.doi.org/10.1158/1078-0432.CCR-04-2642
18. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138-44; PMID:20124182; http://dx.doi.org/10.1200/JCO.2009.24.2024
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http://dx.doi.org/10.1016/S0092-8674(00)81683-9
21. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-57; PMID:16622479; http://dx.doi.org/10.1038/nri1837
22. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013; 341:1192-8; PMID:24031011; http://dx.doi.org/10.1126/science.1241145
23. Schaefer WW, Regula JTJ, Bähner MM, Schanzer JJ, Croasdale RR, Dűrr HH, Gassner CC, Georges GG, Kettenberger HH, Imhof-Jung SS et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
24. Li B, Zhao L, Wang C, Guo H, Wu L, Zhang X, Qian W, Wang H, Guo Y. The protein-protein interface evolution acts in a similar way to antibody affinity maturation. J Biol Chem 2010; 285:3865-71; PMID:20007707; http://dx.doi.org/10.1074/jbc.M109.076547
25. Zhao L, Tong Q, Qian W, Li B, Zhang D, Fu T, Duan S, Zhang X, Zhao J, Dai J et al. Eradication of non-Hodgkin lymphoma through the induction of tumorspecific T cell immunity by CD20-Flex BiFP. Blood 2013; 122:4230-6; PMID:24178967; http://dx.doi.org/10.1182/blood-2013-04-496554
26. Atwell SS, Ridgway JBJ, Wells JAJ, Carter PP. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26-35; http://dx.doi.org/10.1006/jmbi. 1997.1116.
27. Ridgway JB, Presta LG, Carter P. “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
28. Li B, Zhao L, Guo H, Wang C, Zhang X, Wu L, Chen L, Tong Q, Qian W, Wang H et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009; 114:5007-15; PMID:19828699; http://dx.doi.org/10.1182/blood-2009-06-225474
29. Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med 2012; 4:1272-1278; PMID:22461643
30. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160-70; PMID:20708157; http://dx.doi.org/10.1016/j.ccr.2010.06.014
31. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999; 29:2613-24; PMID:10458776; http://dx.doi.org/10.1002/(SICI)1521-4141(199908) 29:08%3c2613::AID-IMMU2613%3e3.0.CO;2-J
32. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200
33. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L, Castedo M, Mignot G, Panaretakis T, Casares N et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
34. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936
35. Lake RA, van der Most RG. A better way for a cancer cell to die. N Engl J Med 2006; 354:2503-4; PMID:16760453; http://dx.doi.org/10.1056/NEJMcibr061443
36. Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004; 305:197-200; PMID:15247468; http://dx.doi.org/10.1126/science.1099688
37. Chao MP, Jaiswal S. Calreticulin is the dominant prophagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2:6394–8; PMID:21178137; http://dx.doi.org/10.1126%2Fscitranslmed.3001375
38. D’Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat 2010; 123:387-96; PMID:19946741; http://dx.doi.org/10.1007/s10549-009-0649-x
39. O’Donovan N, Byrne AT, O’Connor AE, McGee S, Gallagher WM, Crown J. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Invest New Drugs 2011; 29:752-9; PMID:20229355; http://dx.doi.org/10.1007/s10637-010-9415-5
40. Green MD, Francis PA, Gebski V, Harvey V, Karapetis C, Chan A, Snyder R, Fong A, Basser R, Forbes JF et al. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann Oncol 2009; 20:1813-7; PMID:19553291; http://dx.doi.org/10.1093/annonc/mdp202
41. Dickler MN, Cobleigh MA, Miller K D, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced ormetastatic breast cancer. Breast Cancer Res Treat 2009; 115:115-21; PMID:18496750; http://dx.doi.org/10.1007/s10549-008-0055-9
42. Gioulbasanis I, Saridaki Z, Kalykaki A, Vamvakas L, Kalbakis K, Ignatiadis M, Amarantidis K, Kakolyris S, Georgoulias V, Mavroudis D. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial. Anticancer Res 2008; 28:3019-25; PMID:19031950
43. Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EP. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat 2009; 117:615-23; PMID:19294501; http://dx.doi.org/10.1007/s10549-009-0366-5
44. Arteaga CL, O’Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 2008; 14:6277-83; PMID:18829509; http://dx.doi.org/10.1158/1078-0432.CCR-08-0482
45. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15:2452-67; PMID:8665853
46. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010; 16:1373-83; PMID:20179223; http://dx.doi.org/10.1158/1078-0432.CCR-09-1218
47. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61:4744-9;PMID:11406546
48. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR. Rational design and engineering of therapeutic proteins. Drug Discov Today 2003; 8:212-21; PMID:12634013; http://dx.doi.org/10.1016/S1359-6446(03)02610-2
49. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 2007; 179:2815-23; PMID:17709495; http://dx.doi.org/10.4049/jimmunol.179.5.2815
50. Nahta R, Yu D, Hung M-C, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3:269-80; PMID:16683005; http://dx.doi.org/10.1038/ncponc0509
51. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16:3-11; PMID:18846107; http://dx.doi.org/10.1038/cdd.2008.150
52. Savini L, Gaeta A, Fattorusso C, Catalanotti B, Campiani G, Chiasserini L, Pellerano C, Novellino E, McKissic D, Saxena A. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. J Med Chem 2003; 46:1-4; PMID:12502352; http://dx.doi.org/10.1021/jm0255668
53. Gemma S, Gabellieri E, Huleatt P, Fattorusso C, Borriello M, Catalanotti B, Butini S, De Angelis M, Novellin E, Nacci V. et al. Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. J Med Chem 2006; 49:3421-5; PMID:16722663; http://dx.doi.org/10.1021/jm060257t
54. Dauber Osguthorpe P, Roberts VA, Osguthorpe DJ, Wolff J, Genest M, Hagler AT. Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins 1988; 4:31-47; PMID:3054871; http://dx.doi.org/10.1002/prot.340040106
55. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983; 4:187-217; http://dx.doi.org/10.1002/jcc.540040211
56. Im W, Lee MS, Brooks CL. Generalized born model with a simple smoothing function. J Comput Chem 2003; 24:1691-702; PMID:12964188; http://dx.doi.org/10.1002/jcc.10321
57. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000; 33:889-97; PMID:11123888; http://dx.doi.org/10.1021/ar000033j